Arovella Therapeutics Limited (ASX:ALA)


right-arrow Created with Sketch. 0.003 (8.33%)
MCAP $17.31M
Last trade 12.05pm 19/01/2022 20mins delayed

Latest Announcements

14/01/2022ALAArovella Therapeutics Limited
11/01/2022ALAArovella Therapeutics Limited
17/12/2021ALAArovella Therapeutics Limited
17/12/2021ALAArovella Therapeutics Limited
16/12/2021ALAArovella Therapeutics Limited
16/12/2021 Price SensitivePSALAArovella Therapeutics Limited
13/12/2021 Price SensitivePSALAArovella Therapeutics Limited
29/11/2021 Price SensitivePSALAArovella Therapeutics Limited

Company Overview

Arovella Therapeutics Limited, formerly SUDA Pharmaceuticals Limited, is an Australia-based biotechnology company. The Company focuses on specific disease areas, oncology and conditions that affect the central nervous system. It is focused on developing therapies to treat human disease. The Company is developing its invariant natural killer T (iNKT) cell therapy platform to treat blood cancers. The Company's OroMist technology develops oral sprays to reformulate pharmaceuticals. Its ZolpiMist oral spray formulation of zolpidem tartrate to treat short-term insomnia. It is also developing oral sprays to treat migraine headaches, motion sickness, and drug-resistant epilepsy.

ALA in the news

Arovella Therapeutics (ALA) acquires a global exclusive licence agreement for the patent…
Arovella Therapeutics (ALA) receives a $524,000 tax refund from the Australian Taxation…

Search Previous Announcements